Aura raises $80m to develop its virus-like cancer drugsUS biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like Share XAura raises $80m to develop its virus-like cancer drugshttps://pharmaphorum.com/news/aura-raises-80m-to-develop-its-virus-like-cancer-drugs/
Two biotechs target dry eye disease after Novartis’ Xiidra problemsThe pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, Share XTwo biotechs target dry eye disease after Novartis’ Xiidra problemshttps://pharmaphorum.com/news/two-biotechs/
UK patient group warns COVID could limit access to Novartis’ new eye drugNICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales – Share XUK patient group warns COVID could limit access to Novartis’ new eye drughttps://pharmaphorum.com/news/patient-group-warns-covid-limit-access-novartis-eye-drug/
Roche targets wet AMD with faricimab and its 16-week regimenTwin late-stage trials of Roche’s ophthalmology drug faricimab have hit the mark in “wet” age-related macular degeneration trial, Share XRoche targets wet AMD with faricimab and its 16-week regimenhttps://pharmaphorum.com/news/faricimab/
Roche set to file ophthalmology drug faricimab in DMERoche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody Share XRoche set to file ophthalmology drug faricimab in DMEhttps://pharmaphorum.com/news/roche-set-to-file-ophthalmology-drug-faricimab-in-dme/
Novartis signs ophthalmology AI deal with RetinAINovartis has signed a multi-year agreement with RetinAI, which will see the companies work together to use artificial Share XNovartis signs ophthalmology AI deal with RetinAIhttps://pharmaphorum.com/news/novartis-signs-ophthalmology-ai-d/
Janssen adds Hemera’s AMD gene therapy to pipelineJohnson & Johnson’s pharma unit Janssen has bought rights to an investigational gene therapy for a severe form Share XJanssen adds Hemera’s AMD gene therapy to pipelinehttps://pharmaphorum.com/news/janssen-adds-hemeras-amd-gene-therapy-to-ophthalmology-pipeline/
Novartis taps smartpatient for app to support wet AMD patientsGerman digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet Share XNovartis taps smartpatient for app to support wet AMD patientshttps://pharmaphorum.com/news/novartis-taps-smartpatient-for-app-to-support-wet-amd-patients/
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarNovartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its Share XFDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarhttps://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/
